Drug
Sigvotatug Vedotin
Sigvotatug Vedotin: highest development phase Phase 3, developed by Pfizer, Seagen. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Pfizer, Seagen
Trials
| Drug | Phase | Indication |
|---|---|---|
| sigvotatug vedotin NCT06012435 | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| sigvotatug vedotin NCT04389632 | Phase 1 | Carcinoma, Non-Small Cell Lung |
| sigvotatug vedotin NCT06549816 | Phase 1 | Carcinoma, Non-Small Cell Lung |
Latest
Follow Sigvotatug Vedotin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.